Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Rosen

Showing results (41-50 of 207) with videos related to

Pageof 21
Sort By:
Cancer Cell|October 18, 2005
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cellsQing-Bai She, David B Solit, Qing Ye, et al.
Nature Biotechnology|May 11, 2004
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitorsPeter M Smith-Jones, David B Solit, Timothy Akhurst, et al.
Journal of Medicinal Chemistry|April 15, 2005
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90Laura Llauger, Huazhong He, Joungnam Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2009
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathwayChristine A Pratilas, Barry S Taylor, Qing Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutantsDavid R Huron, Mercedes E Gorre, Alan J Kraker, et al.
Cancer Research|July 20, 2006
Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptorsSeungchan Yang, Shimian Qu, Marianela Perez-Tores, et al.
Molecular Systems Biology|September 4, 2008
Models from experiments: combinatorial drug perturbations of cancer cellsSven Nelander, Weiqing Wang, Björn Nilsson, et al.
Cancer Research|August 12, 2010
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signalingEnsar Halilovic, Qing-Bai She, Qing Ye, et al.
Cancer Research|January 30, 2009
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancerDerek S Welsbie, Jin Xu, Yu Chen, et al.
Cancer Cell|July 9, 2010
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumorsQing-Bai She, Ensar Halilovic, Qing Ye, et al.
Pageof 21

Showing results (41-50 of 207) with videos related to

Sort By:
Pageof 21
Cancer Cell|October 18, 2005
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cellsQing-Bai She, David B Solit, Qing Ye, et al.
Nature Biotechnology|May 11, 2004
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitorsPeter M Smith-Jones, David B Solit, Timothy Akhurst, et al.
Journal of Medicinal Chemistry|April 15, 2005
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90Laura Llauger, Huazhong He, Joungnam Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2009
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathwayChristine A Pratilas, Barry S Taylor, Qing Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutantsDavid R Huron, Mercedes E Gorre, Alan J Kraker, et al.
Cancer Research|July 20, 2006
Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptorsSeungchan Yang, Shimian Qu, Marianela Perez-Tores, et al.
Molecular Systems Biology|September 4, 2008
Models from experiments: combinatorial drug perturbations of cancer cellsSven Nelander, Weiqing Wang, Björn Nilsson, et al.
Cancer Research|August 12, 2010
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signalingEnsar Halilovic, Qing-Bai She, Qing Ye, et al.
Cancer Research|January 30, 2009
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancerDerek S Welsbie, Jin Xu, Yu Chen, et al.
Cancer Cell|July 9, 2010
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumorsQing-Bai She, Ensar Halilovic, Qing Ye, et al.
Pageof 21